Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:

CHARM Program: 3 Component trials comparing candesartan with placebo.

Trial profile Fox K et al. Lancet 2008;372:

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

Clinical Outcomes with Newer Antihyperglycemic Agents

ONTARGET Risk factors and outcomes associated with nonadherence Background ONTARGET compared the efficacy of the ARB telmisartan, the ACE inhibitor ramipril,

PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

The Indian Polycap Study (TIPS). Lancet 2009 Mar 30 [Epub]

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.

Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Trial profile The FIELD study investigators, Lancet Published online November 14, 2005.

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

The SPRINT Research Group

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

All-cause mortality by treatment group

HOPE: Heart Outcomes Prevention Evaluation study

Valsartan in Acute Myocardial Infarction Trial Investigators

51st Annual Scientific Session for the LIFE Investigators

The following slides highlight a report on presentations at a Hotline Session and a Satellite Symposium of the European Society of Cardiology 2003 Congress.

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

Baseline characteristics of patients

Trial profile John A Dormandy et al. Lancet 2005;366:

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

CIBIS II: Cardiac Insufficiency Bisoprolol Study II

A: Kaplan-Meier estimate of time to first LLA

Repeated Heart Rate Measurement and Cardiovascular Outcomes in Left Ventricular Systolic Dysfunction Victoria Hamill, PhD, Ian Ford, PhD, Kim Fox, MD,

Challenging the Myths in Heart Failure With Reduced Ejection Fraction

Clinical factors associated with long-term mortality following vascular surgery: Outcomes from The Coronary Artery Revascularization Prophylaxis (CARP)

Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study Vasilios Papademetriou, MD, DSc, Eric.

Volume 14, Issue 12, Pages (December 2017)

Svend A. Mortensen et al. JCHF 2014;2:

Enrollment and Outcomes

Volume 371, Issue 9627, Pages (May 2008)

Volume 378, Issue 9786, Pages (July 2011)

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:

Baseline Characteristics According to Sex

Estimated 5-year rate of a first major vascular event (MVE), major coronary event (MCE),or vascular death in univariate and multivariate risk subgroups.

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Collet JP, et al. Lancet 2009;373:309-17

Associations between β-blocker dosage group, predischarge heart rate group, and the primary composite outcome of death or cardiovascular rehospitalisation.

Baseline Characteristics by hs-CRP

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

Baseline Characteristics of the Patients - Part I

The ACCORD Study Group. NEJM 2010; Epub March 14

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Kaplan-Meier survival estimates for major cardiovascular events.

The selection process for randomised controlled trials (RCTs) and cohort studies on omega 3 fatty acid and health outcomes Lee Hooper, BMJ 2006 Mar 24;

Kaplan-Meier plot for the prespecified primary endpoint (CARE-HF (A) and the secondary composite endpoint (all-cause mortality and new onset heart failure.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

Avasare et al. Am J Nephrol 2017;45:99-106 (DOI: / )

Presentation transcript:

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Baseline characteristics of patients GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Kaplan-Meier curves for time to all-cause death (A) and for time to all-cause death or admission for cardiovascular reasons (B) *Estimates were calculated with a Cox proportional hazards model, with adjustment for admission to hospital for heart failure in the previous year, previous pacemaker, sex, diabetes, pathological Q waves, and angiotensin receptor blockers. GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Secondary outcomes GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Causes of death GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

for cardiovascular reasons Predefined subgroup analysis-composite endpoint of all-cause death or admission to hospital for cardiovascular reasons GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Permanent discontinuations and adverse drug reactions GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]